Equities Analysts Set Expectations for COGT FY2026 Earnings

Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) - Wedbush increased their FY2026 earnings per share estimates for Cogent Biosciences in a research note issued to investors on Monday, June 30th. Wedbush analyst D. Nierengarten now anticipates that the technology company will post earnings per share of ($1.12) for the year, up from their prior forecast of ($1.13). Wedbush has a "Neutral" rating and a $10.00 price target on the stock. The consensus estimate for Cogent Biosciences' current full-year earnings is ($2.42) per share. Wedbush also issued estimates for Cogent Biosciences' FY2027 earnings at ($0.78) EPS and FY2028 earnings at ($0.23) EPS.

Other equities research analysts also recently issued research reports about the company. Scotiabank began coverage on Cogent Biosciences in a research report on Friday, March 7th. They set a "sector outperform" rating and a $17.00 price objective on the stock. Piper Sandler raised Cogent Biosciences to a "strong-buy" rating in a report on Friday, March 7th. Needham & Company LLC reissued a "hold" rating on shares of Cogent Biosciences in a report on Tuesday, June 17th. JPMorgan Chase & Co. raised their price target on Cogent Biosciences from $21.00 to $25.00 and gave the stock an "overweight" rating in a report on Thursday, May 29th. Finally, HC Wainwright lowered their price target on Cogent Biosciences from $14.00 to $12.00 and set a "buy" rating for the company in a report on Tuesday, May 20th. Three investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $14.43.

Cogent Biosciences Stock Performance

COGT stock traded up $0.21 during trading on Thursday, reaching $7.62. 1,862,978 shares of the company traded hands, compared to its average volume of 1,345,019. Cogent Biosciences has a 12 month low of $3.72 and a 12 month high of $12.61. The business has a 50 day simple moving average of $5.92 and a 200 day simple moving average of $6.76. The company has a market capitalization of $867.04 million, a price-to-earnings ratio of -4.14 and a beta of 1.88.

Cogent Biosciences (NASDAQ:COGT - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The technology company reported ($0.52) earnings per share for the quarter, beating analysts' consensus estimates of ($0.56) by $0.04.

Institutional Investors Weigh In On Cogent Biosciences

A number of institutional investors and hedge funds have recently modified their holdings of the company. Balyasny Asset Management L.P. lifted its holdings in shares of Cogent Biosciences by 8.8% during the fourth quarter. Balyasny Asset Management L.P. now owns 20,805 shares of the technology company's stock worth $162,000 after purchasing an additional 1,687 shares during the period. New York State Common Retirement Fund raised its position in Cogent Biosciences by 10.5% during the fourth quarter. New York State Common Retirement Fund now owns 23,102 shares of the technology company's stock valued at $180,000 after acquiring an additional 2,200 shares in the last quarter. Teacher Retirement System of Texas raised its position in Cogent Biosciences by 15.4% during the fourth quarter. Teacher Retirement System of Texas now owns 17,983 shares of the technology company's stock valued at $140,000 after acquiring an additional 2,396 shares in the last quarter. Arizona State Retirement System raised its position in Cogent Biosciences by 18.0% during the first quarter. Arizona State Retirement System now owns 20,567 shares of the technology company's stock valued at $123,000 after acquiring an additional 3,142 shares in the last quarter. Finally, MetLife Investment Management LLC raised its position in Cogent Biosciences by 6.3% during the fourth quarter. MetLife Investment Management LLC now owns 56,750 shares of the technology company's stock valued at $443,000 after acquiring an additional 3,382 shares in the last quarter.

About Cogent Biosciences

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.